Kazia Therapeutics Executes Deal With QIMR Berghofer Medical to Obtain Intellectual Property License
Kazia Therapeutics (KZIA) said Thursday it has executed a deal with QIMR Berghofer Medical Research Institute, an Australian cancer research center, to receive a license for certain intellectual property to develop any drugs or product candidates within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors.
Financial terms weren't disclosed.
The company first partnered with the cancer research center in December 2022, Kazia added.
Shares of the company were up 3% in recent Thursday premarket activity.
Price: 0.3780, Change: +0.01, Percent Change: +3.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.